CRISPR Therapeutics AG Common Shares (CRSP)
Stock · NASDAQ · Health Care
$49.28as of 10/16/2026
Price chart
Active signals
CRSP Signal Track Record
How signals performed across all stocks →What CRSP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | -3.3% | 34% | September 3, 2026 |
| Bollinger Band Breakout | 27 | -5.2% | 41% | August 19, 2026 |
| Bollinger Band Breakdown | 19 | -0.7% | 42% | January 30, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -5.9% | 39% | October 9, 2026 |
| Any 20-session window (baseline) | -1.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Website
- crisprtx.com/
Fundamentals
- 1-day range
- $49.76$51.88
- Market cap
- $4.99B
- P/E (trailing)
- —
- P/E (forward)
- -14.49
- EPS (trailing)
- $-4.76
- Dividend yield
- —
- Beta
- 1.93
- Avg. volume
- 1.59M
How CRISPR Therapeutics AG Common Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
19 analyst ratings
CRISPR Therapeutics AG Common Shares Competitors
Chosen by industry and closest market cap.
- CRSPCRISPR Therapeutics AG Common Shares$49.25▼ 4.41%Market cap $4.99BP/E —$44.12$75.06
- DNLIDenali Therapeutics Inc. Common Stock$17.61▼ 3.98%Market cap $3.92BP/E —$13.75$27.3
- RLAYRelay Therapeutics Inc. Common Stock$16.28▼ 5.90%Market cap $3.78BP/E —$5.95$21.27
- ADPTAdaptive Biotechnologies Corporation Common Stock$24.02▼ 6.10%Market cap $3.77BP/E —$12$30.74
- SRRKScholar Rock Holding Corporation Common Stock$39.9▼ 1.82%Market cap $6.31BP/E —$27.07$61.76
- CGONCG Oncology Inc. Common stock$59.85▼ 3.25%Market cap $6.60BP/E —$35.8$80.97
- TWSTTwist Bioscience Corporation Common Stock$132.75▼ 8.13%Market cap $6.84BP/E —$23.3$219.71
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG Common Shares | $4.99B | — | $49.25 | ▼ 4.41% | $44.12$75.06 |
| DNLI Denali Therapeutics Inc. Common Stock | $3.92B | — | $17.61 | ▼ 3.98% | $13.75$27.3 |
| RLAY Relay Therapeutics Inc. Common Stock | $3.78B | — | $16.28 | ▼ 5.90% | $5.95$21.27 |
| ADPT Adaptive Biotechnologies Corporation Common Stock | $3.77B | — | $24.02 | ▼ 6.10% | $12$30.74 |
| SRRK Scholar Rock Holding Corporation Common Stock | $6.31B | — | $39.9 | ▼ 1.82% | $27.07$61.76 |
| CGON CG Oncology Inc. Common stock | $6.60B | — | $59.85 | ▼ 3.25% | $35.8$80.97 |
| TWST Twist Bioscience Corporation Common Stock | $6.84B | — | $132.75 | ▼ 8.13% | $23.3$219.71 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.Yahoo · 10/9/2026
- ARGX Stock Down on Stopping Late-Stage Autoimmune Disease StudyYahoo · 10/9/2026
- AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in CancerYahoo · 10/8/2026
- Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashYahoo · 10/8/2026
- CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026Yahoo · 10/8/2026
- Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?Yahoo · 10/7/2026
- CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You TradeYahoo · 10/6/2026
- Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’benzinga · 10/6/2026
- Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’Benzinga · 10/6/2026
Insider Activity
Insider Actions →- James R. Kasinger · October 6, 2026 · Option Exercise2.0K @ $13.62
- James R. Kasinger · October 6, 2026 · Sale2.0K @ $60.04
- James R. Kasinger · September 22, 2026 · Sale10.4K @ $60.24
- James R. Kasinger · September 22, 2026 · Option Exercise10.4K @ $13.62
- Ali Behbahani · September 17, 2026 · Option Exercise30.0K @ $14
- Ali Behbahani · September 17, 2026 · Sale13.7K @ $57.09
- Raju Prasad · August 7, 2026 · Gift750
- Fleming Harold Edward · June 5, 2026 · Grant13.0K
- Rommel Christian · June 5, 2026 · Grant13.0K
- Treco Douglas A · June 5, 2026 · Grant13.0K
- Morrison Briggs · June 5, 2026 · Grant13.0K
- Katherine A. High · June 5, 2026 · Grant13.0K
- Ali Behbahani · June 5, 2026 · Grant13.0K
- Greene John · June 5, 2026 · Grant13.0K
- George Simeon · June 5, 2026 · Grant13.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
CRISPR Therapeutics to Share New Data at AHA and ACR 2026
CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.
CRISPR Therapeutics to Share New Data at AHA and ACR 2026. CRISPR Therapeutics announced it will present late-breaking data at the American Heart Association and American College of Rheumatology conferences in 2026. These upcoming presentations are key events for the company, as they will provide new clinical insights into its treatments for heart and autoimmune conditions. The stock is currently trading near its 52-week low, making these data releases a significant factor for investors watching the company's progress.